Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has signed an Informed Consent Form(ICF).~2. Patient Must not be pregnant or breastfeeding and agree to use birth control~3. Patient meets the colonoscopy requirements defined by the American Gastroenterological Association guidelines and no clinically-significant laboratory or physical examination findings;~4. Patient meets protocol-defined criteria for Irritable Bowel Syndrome with Constipation(IBS-C), including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria~5. Patient meets protocol-defined eDiary completion Compliance and agrees to refrain from making any new, major life-style changes that may affect IBS-C symptoms~Exclusion Criteria:~1. Recent history of mushy or watery stools~2. Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study~3. Patient currently has both unexplained and clinically significant alarm symptoms or systemic signs of infection or colitis.~4. Surgery to the gastrointestinal tract~5. Usage of prohibited medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- controlled arm (Type: PLACEBO_COMPARATOR): None
- treatment arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).